Scholar Rock finally won FDA approval. Why did SRRK stock fall 6% when ISEMBYLD launched?
Scholar Rock starts its ISEMBYLD SMA launch after FDA approval, but SRRK falls as investors weigh a roughly $310,000 annual price and execution.
Pharma & Biotech
Features & Analysis
Scholar Rock has its first FDA-approved drug. How big can ISEMBYLD become alongside existing SMA therapies?
ISEMBYLD is not replacing the therapies that transformed spinal muscular atrophy treatment. Scholar Rock is asking physicians and payers to add a muscle-targeted medicine on top of them, creating a commercial proposition that could expand the market while also making reimbursement and treatment logistics central to adoption.
Pharma & Biotech
Apitegromab survives another manufacturing hurdle: Can Scholar Rock still secure FDA approval by September 30?
Scholar Rock shifts apitegromab’s FDA review to a second fill-finish site as its September 30 SMA decision date remains on track.